Prexa Pulls In $7M From Advent, Shire

Prexa Pharmaceuticals, a Boston-based biotech developing experimental drugs for treating central nervous disorders, announced it wrapped up a $7 million Series B funding round from Advent Healthcare Ventures and new investor Shire Pharmaceuticals. Prexa, which previously raised $3.1 million in Series A money, was co-founded by Advent in 2006 and is working on molecules to safely enhance dopamine activity and norepinephrine activity, to improve on existing treatments for for ADHD, depression and Parkinson’s disease.

Trending on Xconomy